At the news
? NEUTRALIMPACT 3/10 SC 13G/A filed Nov 6, 2026 at 10:58 ET
T. Rowe Price Investment Management filed an amended Schedule 13G disclosing a 9.6% passive stake in Vaxcyte as of September 30, 2026, up from a prior filing. The increase in a passive holding is neutral; the filing follows positive Phase 3 data for VAX-31 and a $1.1B capital raise reported two days earlier.
- T. Rowe Price Investment Management reported beneficial ownership of 14,312,368 shares of Vaxcyte common stock as of September 30, 2026.
- The stake represents 9.6% of shares outstanding.
- This is an amendment (SC 13G/A) updating a prior passive stake filing.
- The filing certifies the securities were acquired and held in the ordinary course of business, not to influence control.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access